HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 6262Erstellt: 25. Oktober 2026
L-(-)-Ornithine
polyornithine · L-Ornithine, homopolymer
https://huagongshe.com/de/chemical/6262
Identifikatoren & physikalische Daten
| CAS No. | 25104-12-5 |
|---|
| Summenformel | C5H12N2O2 |
|---|
| Durchschnittliche Molmasse | 132,16 g/mol |
|---|
| Monoisotopische Masse | 132,08987762 g/mol |
|---|
| SMILES | NCCC[C@H](N)C(=O)O |
|---|
| InChIKey | AHLPHDHHMVZTML-BYPYZUCNSA-N |
|---|
| PubChem CID | 6262 |
|---|
| ChEMBL | CHEMBL446143 |
|---|
| ChEBI | CHEBI:15729 |
|---|
| EC No. | 200-731-7 |
|---|
| DTXSID | DTXSID00883219 |
|---|
Chemische & physikalische Eigenschaften
| XLogP | -4,4 |
|---|
| Polarare Oberfläche (TPSA) | 89,3 |
|---|
| H-Brücken-Donoren | 3 |
|---|
| H-Brücken-Akzeptoren | 4 |
|---|
| Frei drehbare Bindungen | 4 |
|---|
| Schwere Atome | 9 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 95 |
|---|
| Stoffklassen | Biological Agents -> Amino Acids and Derivatives |
|---|
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
|---|
| Kosmetika | Skin conditioning |
|---|
| SpringerMaterials Properties | 15N nuclear magnetic resonance spectrum |
|---|
| LogP (Verteilungskoeffizient) | -4.22 |
|---|
| Löslichkeit | Appreciable620 mg/mL |
|---|
| Schmelzpunkt | 140 °C |
|---|
| Physical Description | Colorless solid[Merck Index] |
|---|
| Dissociation Constants | 1.94 (at 25 °C) |
|---|
| Collision Cross Section | 127.7 Ų [M+H]+ [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]129.79 Ų [M+H]+ [CCS Type: DTMethod: stepped-field]127.81 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]121 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine] |
|---|
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 100% (6 of 6) of all reports.Not ClassifiedAggregated GHS information provided per 6 reports by companies from 2 notifications to the ECHA C&L Inventory. |
|---|
| Regulatorische Informationen | Chemical: L-OrnithineStatus: Active Update: 13-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/23820L-Ornithine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
|---|
| Weitere Sicherheitsinformationen | IMAP assessments - L-Ornithine: Environment tier I assessment |
|---|
| Hazard Classes and Categories | Not Classified |
|---|
| Gesundheitliche Auswirkungen | Chronically high levels of ornithine are associated with at least 9 inborn errors of metabolism including: Cystathionine Beta-Synthase Deficiency, Hyperornithinemia with gyrate atrophy, Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, Hyperprolinemia Type II, Lysinuric Protein Intolerance, Ornithine Aminotransferase Deficiency, Ornithine Transcarbamylase Deficiency and Prolinemia Type II. |
|---|
| Expositionspfade | Absorbed from the small intestine via a sodium-dependent active transport process |
|---|
| Toxizitätsübersicht | L-Ornithine is metabolised to L-arginine. L-arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of L-arginine in tissues throughout the body. As De novo synthesis of L-arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, L-ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to L-arginine). |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Toxicity Data | Oral, rat LD<sub>50</sub> = 10000 mg/kg |
|---|
